Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …

Background Convalescent plasma therapy is a leading treatment for conferring temporary
immunity to COVID-19–susceptible individuals or for use as post-exposure prophylaxis …

The development of neutralizing antibodies (NAbs) against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) following infection or vaccination is likely to be …

BACKGROUND SARS-CoV-2–specific antibodies may protect from reinfection and disease,
providing rationale for administration of plasma containing SARS-CoV-2–neutralizing …

Background The development of neutralizing antibodies (NAbs) against SARS-CoV-2,
following infection or vaccination, is likely to be critical for the development of sufficient …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Passive transfer of antibodies from COVID-19 convalescent patients is being used as an
experimental treatment for eligible patients with SARS-CoV-2 infections. The United States …

We evaluated the antibody responses in 259 potential convalescent plasma donors for
Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies …

SARS-CoV-2 is a newly identified member of the coronavirus family that has caused the
Coronavirus disease 2019 (COVID-19) pandemic. This rapidly evolving and unrelenting …

BACKGROUND Neutralizing antibodies are considered a key correlate of protection by
current SARS-CoV-2 vaccines. The manner in which human infections respond to …